e-learning
resources
Vienna 2012
Monday, 03.09.2012
COPD treatments: efficacy and safety
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination can decrease mortality of COPD patients, a nationwide population-based cohort study in Taiwan
M.C. Chan, G.H. Lin (Taichung, Taiwan)
Source:
Annual Congress 2012 - COPD treatments: efficacy and safety
Session:
COPD treatments: efficacy and safety
Session type:
Thematic Poster Session
Number:
2114
Disease area:
Airway diseases
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) remains a major public health problem. Current treatments, including pharmacological and non-pharmalogical, can only alleviate symptoms, prevent exacerbation and improve quality of life. Previous large-scale studies failed to demonstrate benefit of mortality reduction which is also important for a chronic illness.
Objective: The aim of this study is to determine whether ICS/LABA combination can reduce mortality of COPD by using Taiwan National Health Insurance Database.
Method: This was a nationwide population-based cohort study. A total of 1989 COPD patients were identified from one million sampling cohort dataset between January to December in 2005. Patients with diagnosed in 2005 as COPD were grouped as non-controller use (n=1638), ICS/LABA (n=265) and LAMA (n=86). Cox regression model was used to evaluate the incidence of mortality and pneumonia in the following 3 years to December 2008.
Result: The incidence of pneumonia was not different among three groups. However, COPD patients with older age (H.R. 1.398 for every increase of 10 years, p < 0.0001) and male gender (H.R. 1.414, p < 0.001) had higher incidence to have pneumonia. The mortality rate was lower in patients who use ICS/LABA combination as compared with non-controller group (H.R. 0.694, p = 0.0165)
Conclusion: In the selected Taiwanese population, COPD mortality was lower among patients who used ICS/LABA. Incidence of pneumonia was not increased with ICS/LABA, but significantly related increased age and male gender.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M.C. Chan, G.H. Lin (Taichung, Taiwan). Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination can decrease mortality of COPD patients, a nationwide population-based cohort study in Taiwan. Eur Respir J 2012; 40: Suppl. 56, 2114
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA)
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study
Source: Eur Respir J, 53 (6) 1801257; 10.1183/13993003.01257-2018
Year: 2019
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Three-year prospective cohort study of growth in asthmatic children prescribed appropriate inhaled corticosteroid (ICS) doses
Source: Eur Respir J 2004; 24: Suppl. 48, 614s
Year: 2004
Inhaled corticosteroid therapy and risk of hospitalization with pneumonia: a population-based case-control study from Denmark
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
Sub-optimal asthma control with medium- or high-dose ICS/LABA: a retrospective cohort study from Japan claims database
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016
Source: Eur Respir J, 53 (4) 1802130; 10.1183/13993003.02130-2018
Year: 2019
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
The use of high-dose inhaled corticosteroids and add-on therapy in children in the UK: an observational study of 4332 patients
Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Year: 2004
Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study
Source: ERJ Open Res, 6 (1) 00246-2019; 10.1183/23120541.00246-2019
Year: 2020
Factors related to discontinuous use of inhaled drugs in COPD patients: A population-based cohort study in Lazio (Italy)
Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD
Year: 2012
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
High-dose inhaled corticosteroids and add-on therapy use in adults in the UK: an observational study of 22,027 patients
Source: Annual Congress 2004 - Primary care: asthma
Year: 2004
Inhaled corticosteroids and FEV1 decline in asthma: an international cohort study
Source: International Congress 2018 – Asthma in children and adults: long-term aspects
Year: 2018
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Inhaled steroids doses to obtain asthma control in children: a randomised concurrent cohort study
Source: Annual Congress 2009 - Clinical advances in childhood asthma
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept